Molecular Approaches in HFpEF: MicroRNAs and iPSC-Derived Cardiomyocytes. J Cardiovasc Transl Res 2017 Jun;10(3):295-304
Date
12/30/2016Pubmed ID
28032312Pubmed Central ID
PMC5937699DOI
10.1007/s12265-016-9723-zScopus ID
2-s2.0-85007413634 (requires institutional sign-in at Scopus site) 9 CitationsAbstract
Heart failure with preserved left ventricular ejection fraction (HFpEF) has emerged as one of the largest unmet needs in cardiovascular medicine. HFpEF is increasing in prevalence and causes significant morbidity, mortality, and health care resource utilization. Patients have multiple co-morbidities which contribute to the disease complexity. To date, no effective treatment for HFpEF has been identified. The paucity of cardiac biopsies from this patient population and the absence of well-accepted animal models limit our understanding of the underlying molecular mechanisms of HFpEF. In this review, we discuss combining state-of-the-art technologies of microRNA profiling and human induced pluripotent cell-derived cardiomyocytes (iPSC-CMs) in order to uncover novel molecular pathways that may contribute to the development of HFpEF. Here, we focus the advantages and limitations of microRNA profiling and iPSC-CMs as a disease model system to discover molecular mechanisms in HFpEF.
Author List
Kriegel AJ, Gartz M, Afzal MZ, de Lange WJ, Ralphe JC, Strande JLAuthor
Melanie Gartz PhD Assistant Professor in the Cell Biology, Neurobiology and Anatomy department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AnimalsCell Line
Gene Expression Regulation
Heart Failure
Humans
Induced Pluripotent Stem Cells
MicroRNAs
Myocytes, Cardiac
Phenotype
Signal Transduction
Stroke Volume
